Campbell & CO Investment Adviser LLC Invests $2.39 Million in Ascendis Pharma A/S $ASND

Campbell & CO Investment Adviser LLC acquired a new position in shares of Ascendis Pharma A/S (NASDAQ:ASND) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 12,009 shares of the biotechnology company’s stock, valued at approximately $2,388,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Perceptive Advisors LLC acquired a new stake in Ascendis Pharma A/S during the 2nd quarter worth approximately $166,367,000. Adage Capital Partners GP L.L.C. increased its position in shares of Ascendis Pharma A/S by 40.4% during the second quarter. Adage Capital Partners GP L.L.C. now owns 459,606 shares of the biotechnology company’s stock worth $79,328,000 after acquiring an additional 132,201 shares in the last quarter. Marshall Wace LLP lifted its holdings in shares of Ascendis Pharma A/S by 425.5% in the second quarter. Marshall Wace LLP now owns 117,162 shares of the biotechnology company’s stock valued at $20,222,000 after purchasing an additional 94,868 shares in the last quarter. Braun Stacey Associates Inc. bought a new stake in shares of Ascendis Pharma A/S in the 3rd quarter worth $18,678,000. Finally, Qube Research & Technologies Ltd lifted its position in shares of Ascendis Pharma A/S by 83.4% during the 2nd quarter. Qube Research & Technologies Ltd now owns 201,044 shares of the biotechnology company’s stock worth $34,700,000 after buying an additional 91,412 shares in the last quarter.

Analyst Ratings Changes

Several research firms recently commented on ASND. Wolfe Research started coverage on Ascendis Pharma A/S in a research note on Tuesday, November 18th. They issued a “peer perform” rating and a $255.00 price objective on the stock. Wall Street Zen cut shares of Ascendis Pharma A/S from a “buy” rating to a “hold” rating in a research report on Saturday, November 15th. Cowen reiterated a “buy” rating on shares of Ascendis Pharma A/S in a report on Wednesday, January 7th. JPMorgan Chase & Co. boosted their price target on Ascendis Pharma A/S from $260.00 to $264.00 and gave the company an “overweight” rating in a report on Thursday, October 9th. Finally, Wedbush reiterated an “outperform” rating and issued a $220.00 price objective on shares of Ascendis Pharma A/S in a report on Tuesday, November 18th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $262.69.

Ascendis Pharma A/S Stock Performance

Shares of Ascendis Pharma A/S stock opened at $205.83 on Friday. Ascendis Pharma A/S has a one year low of $118.03 and a one year high of $229.94. The stock has a market cap of $12.76 billion, a P/E ratio of -46.36, a P/E/G ratio of 1.14 and a beta of 0.46. The stock’s fifty day moving average is $208.70 and its 200 day moving average is $197.79.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its earnings results on Thursday, November 13th. The biotechnology company reported ($1.17) earnings per share for the quarter, missing the consensus estimate of ($0.41) by ($0.76). The company had revenue of $250.71 million for the quarter, compared to the consensus estimate of $246.91 million. Analysts predict that Ascendis Pharma A/S will post -4.34 EPS for the current year.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.